About
Management
Investors
Events
News
Contact
CSE: CMND
OTC: CMNDF
FWB: CMY0
News Releases
Below are the latest News Releases for Clearmind Medicine Inc.
19
January
Clearmind Medicine to Host “Psychedelics for Alcoholism: From Molecule to Medicine” Virtual Event on January 26
Read More
13
January
Mark Haden, Clearmind Medicine's VP of Business Development Presented at The Canadian Psychedelics Association Event
Read More
11
January
Clearmind Medicine Strengthens Presence in North America with New Senior Appointments
Read More
24
November
Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound
Read More
22
November
Clearmind Medicine to Pursue Dual Listing on Nasdaq
Read More
18
November
Clearmind Medicine Engages Bar-Ilan University to Evaluate Anti-Addictive Properties of Clearmind's Proprietary MEAI Compound
Read More
8
November
Clearmind Medicine Announces Sponsorship of Wonderland Psychedelic Conference in Miami
Read More
26
October
Clearmind Signs Development and Supply Agreement to Produce its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
Read More
14
October
Clearmind Medicine Appoints Distinguished Addiction Experts
Read More
13
October
Clearmind Medicine Files Provisional Patent Application
Read More
7
October
Clearmind Medicine Partners With Clinipace
Read More
1
October
Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
Read More
27
September
Clearmind Medicine To Fund Second R&D Partnership With Hebrew University's Technology Transfer Company
Read More
21
September
Clearmind Medicine Partners with The Hebrew University to Develop Novel Psychedelic Drug
Read More
2
September
Oded Gilboa and Oz Adler Appointed to Board of Directors
Read More
Next
